(NASDAQ: MTVA) Metavia's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.61%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.05%.
Metavia's earnings in 2026 is -$13,125,000.On average, 5 Wall Street analysts forecast MTVA's earnings for 2026 to be -$13,098,908, with the lowest MTVA earnings forecast at -$18,675,395, and the highest MTVA earnings forecast at -$10,140,240. On average, 5 Wall Street analysts forecast MTVA's earnings for 2027 to be -$12,677,495, with the lowest MTVA earnings forecast at -$23,331,591, and the highest MTVA earnings forecast at -$5,856,396.
In 2028, MTVA is forecast to generate -$8,322,899 in earnings, with the lowest earnings forecast at -$12,298,431 and the highest earnings forecast at -$4,771,878.